Drug Trial Radar · NCT00036556
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Aug 15, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
941
Actual
Start
Jun 2001
Primary completion
Not stated
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Male only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
Conditions
- Prostatic Neoplasms
Interventions
AtrasentanDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-to-disease progression will be determined by the time to onset of the earliest of one of the following events: New skeletal lesions, new metastatic extra-skeletal lesions, or an event due to metastatic prostate cancer.Time frame: Every 12 weeks
Locations
234 sites in 17 countries. Site status is shown where the registry gives one.
Urology Centers Of Alabama
Homewood, Alabama
Alaska Clinical Research Center, LLC
Anchorage, Alaska
Advanced Clinical Trials
Tucson, Arizona
Arkansas Urologial Associates, PA
Little Rock, Arkansas
Robin V. Smith, MD
Chula Vista, California
Urology Associate Of Central California
Fresno, California
South Valley Medical Plaza
Gilroy, California
San Diego Urology Center
La Mesa, California
South Orange County Medical Research Center
Laguna Hills, California
UCLA School of Medicine
Los Angeles, California
VA Palo Alto
Palo Alto, California
Hillcrest Urological Medical Group, Inc.
San Diego, California
Urology Associates Of San Luis Obispo
San Luis Obispo, California
Pacific Clinical Research
Santa Monica, California
Western Clinical Research, Inc.
Torrance, California
Urology Associate, Pc
Denver, Colorado
South Fl Medical Research
Aventura, Florida
Clinical Physiology Associates
Fort Myers, Florida
Advanced Research Institute
New Port Richey, Florida
Dattoli Cancer Center
Sarasota, Florida
Urology Treatment Center
Sarasota, Florida
Southeastern Urological Center, P.A.
Tallahassee, Florida
Peachtree Hematology/Oncology Consultants
Atlanta, Georgia
Emory Clinic
Atlanta, Georgia
Sandy Springs Urology
Atlanta, Georgia
Atlanta Va Medical Center
Decatur, Georgia
Dreyer Medical Clinic
Aurora, Illinois
Northwestern University Medical School
Chicago, Illinois
Progressive Care, S.C.
Chicago, Illinois
Christopher Ryan, MD
Chicago, Illinois
Weiss Memorial Hospital
Chicago, Illinois
Evanston Hospital Kellogg Cancer Center
Evanston, Illinois
Welborn Clinic
Evansville, Indiana
Welborn Clinic -East
Evansville, Indiana
Urologic Associates, Pc
Davenport, Iowa
Iowa Urology
Des Moines, Iowa
Kansas University Medical Center
Kansas City, Kansas
Regional Urology
Shreveport, Louisiana
LSUHSC
Shreveport, Louisiana
Johns Hopkins Oncology Center
Baltimore, Maryland
Showing 40 of 234 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.